Who is sponsoring NCT00336986?

NCT00336986 is sponsored by Novo Nordisk A/S.

What condition does NCT00336986 study?

NCT00336986 studies Cancer, Malignant Melanoma.

What drugs are being tested in NCT00336986?

Interventions: recombinant interleukin-21.

What is the status of NCT00336986?

NCT00336986 is currently COMPLETED.

Last reviewed 2023-08-10 · How we verify

An Open-label, Dose Escalation Safety and Tolerability Study of Recombinant Human Interleukin-21 (Phase 1) Followed by an Open-label Treatment Study (Phase 2a) in Patients With Stage IV Malignant Melanoma

NCT00336986 Phase 2 COMPLETED

This trial is conducted in Oceania. A phase 2a study to assess the effect on tumor size. At least 14 to a maximum of 40 patients, who have not previously received treatment for their stage IV disease, will be treated for 6 weeks. IL-21 will be administered intravenously.

Details

Lead sponsor	Novo Nordisk A/S
Phase	Phase 2
Status	COMPLETED
Enrolment	54
Start date	2004-09
Completion	2007-10

Conditions

Cancer
Malignant Melanoma

Interventions

recombinant interleukin-21

Primary outcomes

Tumor size assessed according to international criteria — After 8 weeks

Countries

Australia